Artificial Intelligence
in Precision Medicine
Our drug design technology integrates fundamental principles of
physics with advanced machine learning algorithms to intricately
craft antibodies, protein binders, pepti domimetics, and small-
molecule drugs.
Artificial Intelligence
in Precision Medicine
Our drug design technology integrates
fundamental principles of physics with
advanced machine learning algorithms
to intricately craft antibodies,
protein binders, pepti domimetics,
and small-molecule drugs.

Antibody Design

Elevating antibody therapeutics with data-driven AI. Building on advances in generative and language model-based methods for explorative CDR backbone design, combined with deimmunization and paratope-based functional antibody classification, our approach aims to illuminate the blueprint of epitope-specific antibody design.

Protein/Peptide Binder Design

De novo design of proteins with desirable functions. Leveraging advanced deep learning methods for generative protein backbone design, exploration of protein conformational space, and accurate predictions of protein-protein interactions, combined with robust molecular dynamics simulations, our approach crafts therapeutic solutions that redefine the landscape of intricate protein-based drug development.

Small-Molecule Drug Design

Engineering at the molecular scale for drug-target selectivity. Through seamless integration of AI-driven exploration of protein conformational heterogeneity with generative drug designs aided by expertise in medicinal chemistry, our high throughput virtual screening approach guarantees swift and inventive drug candidate discovery.
[한국경제] AI신약개발사 아론티어, 셀트리온제약과 신약개발 나서
NEWS

[한국경제] AI신약개발사 아론티어, 셀트리온제약과 신약개발 나서

단백질 구조를 기반으로 인공지능(AI)을 활용해 신약을 개발하는 아론티어가 셀트리온제약과 신약개발을 협업하기로 했다. 아론티어는 셀트리온제약와 신약 개발에 대한 업무협약(MOU)을 체결했다고 26일 밝혔다....
Read More
[대덕넷] 문제 해결 전략가 AI···신약 개발 더 빠르고, 정확하게 성공시킨다
NEWS

[대덕넷] 문제 해결 전략가 AI···신약 개발 더 빠르고, 정확하게 성공시킨다

바이오헬스케어협회 '맞춤형 신약 개발 AI 솔루션' 주제로 진행고준수 아론티어 대표 "단백질 디자인 기술에 AI활용 유용해" 인공지능(AI)이 신약 개발에 활용되면서 정밀...
Read More
[더바이오] [단독] 파멥신, AI 기술 접목한다…”아론티어와 차세대 항체 개발 플랫폼 구축”
NEWS

[더바이오] [단독] 파멥신, AI 기술 접목한다…”아론티어와 차세대 항체 개발 플랫폼 구축”

[더바이오 이영성 기자] 차세대 항체치료제 개발 전문기업 파멥신(PharmAbcine)이 인공지능(AI)을 활용한 항체기반 혁신신약 개발과 차세대 플랫폼 구축에 나선다. 10일 업계에 따르면, 파멥신은...
Read More
{"slide_show":3,"slide_scroll":1,"dots":"true","arrows":"true","autoplay":"true","autoplay_interval":3000,"speed":600,"loop":"true","design":"design-2"}

News

Up-To-Date News about Arontier which is an artificial intelligence-driven drug discovery start-up company using bioinformatics, pharmacogenomics for incurable and rare diseases.

Our partners

ARONTIER TEL: +82-2-597-0365 | FAX: +82-2-587-0365 | Email: arontier@arontier.co

ARONTIER TEL: +82-2-597-0365
FAX: +82-2-587-0365
Email: arontier@arontier.co

ADDRESS : 15F, 241, Gangnam-daero, Seocho-gu, Seoul, Republic of Korea
Copyright 2018~2021 ARONTIER. All Rights Reserved.